Artisan Partners Limited Partnership lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.6% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 998,407 shares of the biopharmaceutical company’s stock after selling 37,430 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.78% of Halozyme Therapeutics worth $12,800,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also made changes to their positions in HALO. Wells Fargo & Company MN grew its position in shares of Halozyme Therapeutics by 22.5% during the 1st quarter. Wells Fargo & Company MN now owns 303,626 shares of the biopharmaceutical company’s stock worth $3,935,000 after buying an additional 55,719 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Halozyme Therapeutics by 27.3% during the 1st quarter. Bank of New York Mellon Corp now owns 1,806,490 shares of the biopharmaceutical company’s stock worth $23,412,000 after buying an additional 387,486 shares in the last quarter. Karp Capital Management Corp bought a new position in shares of Halozyme Therapeutics during the 1st quarter worth $188,000. Sei Investments Co. grew its position in shares of Halozyme Therapeutics by 0.8% during the 1st quarter. Sei Investments Co. now owns 309,725 shares of the biopharmaceutical company’s stock worth $4,014,000 after buying an additional 2,605 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its position in shares of Halozyme Therapeutics by 37.2% during the 1st quarter. Parametric Portfolio Associates LLC now owns 52,784 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 14,308 shares in the last quarter. 85.06% of the stock is currently owned by institutional investors.

HALO has been the topic of a number of recent research reports. ValuEngine raised Halozyme Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. BidaskClub raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 16th. Barclays PLC reissued an “overweight” rating and set a $16.00 price target on shares of Halozyme Therapeutics in a research report on Friday, June 23rd. Canaccord Genuity set a $16.00 price target on Halozyme Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Finally, Jefferies Group LLC reissued an “underperform” rating and set a $7.00 price target (up previously from $6.75) on shares of Halozyme Therapeutics in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. Halozyme Therapeutics has an average rating of “Hold” and an average target price of $16.00.

TRADEMARK VIOLATION NOTICE: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/halozyme-therapeutics-inc-halo-shares-sold-by-artisan-partners-limited-partnership/1578022.html.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) opened at 16.68 on Thursday. The stock’s 50 day moving average price is $13.01 and its 200-day moving average price is $13.28. Halozyme Therapeutics, Inc. has a 52-week low of $8.18 and a 52-week high of $17.55. The company’s market cap is $2.24 billion.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.02. The firm had revenue of $33.80 million during the quarter, compared to analyst estimates of $31.76 million. During the same period in the previous year, the firm posted ($0.21) earnings per share. The company’s quarterly revenue was up 1.2% compared to the same quarter last year. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post ($0.22) earnings per share for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.